- Acceleron Pharma (XLRN +7%) and collaboration partner Celgene (NASDAQ:CELG +0.4%) announce FDA approval of Reblozyl (luspatercept-aamt) for the treatment of anemia in adult beta thalassemia patients who require regular red blood cell transfusions.
- The companies will co-promote the product in the U.S.